Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Hematology

Living with Myelofibrosis: Monitoring and Self-Care

At a Glance

Living with myelofibrosis involves regular blood counts, symptom and spleen monitoring, and care plans that change with treatment response. Pacing activities, eating small nutrient-dense meals, and coordinating medicines before procedures can help protect quality of life.

Living with myelofibrosis (MF) is a journey of ongoing management rather than a single event. Because it is a chronic condition, the goal of long-term care is to maintain your quality of life, monitor for disease changes, and manage symptoms as they arise [1][2]. Building a relationship with a care team—ideally one that includes a specialist in myeloproliferative neoplasms (MPNs)—ensures that your monitoring is as precise and proactive as possible [3][4].

Routine Surveillance: What to Expect

Your follow-up schedule is tailored to your risk level and how you are responding to treatment. Standard monitoring usually includes:

  • Complete Blood Counts (CBC): Used to track your hemoglobin, platelets, and white blood cell levels. The frequency of these tests may range from weekly when starting a new drug like ruxolitinib to every few months once you are stable [5][6].
  • Symptom Tracking: Doctors recommend using a validated tool like the MPN-10 (Symptom Assessment Form). This 0–10 scale helps you and your doctor objectively track ten core symptoms, including fatigue, night sweats, and bone pain [7][1].
  • Spleen Monitoring: Your doctor will regularly check your spleen size through physical exams (palpation) or, in some cases, ultrasound or MRI to see if it is responding to therapy [8][9].
  • Periodic Marrow Review: While not done at every visit, repeat bone marrow biopsies or genetic testing may be needed if your blood counts change unexpectedly or if your doctor suspects the disease is progressing [10][11].

Day-to-Day Management Strategies

Managing MF often requires small but meaningful adjustments to your daily routine:

  • Managing Fatigue: Fatigue is a persistent challenge that affects a large portion of patients [12]. Experts recommend pacing—breaking tasks into smaller steps and scheduling rest periods throughout the day—rather than trying to “push through” it [12].
  • Managing Early Satiety: If an enlarged spleen makes you feel full after only a few bites, try eating five to six small meals a day rather than three large ones [13][14]. Focus on nutrient-dense foods to prevent unintentional weight loss [15].
  • Managing Bone Pain: Deep aching in the bones or joints can occur. Keeping your care team informed about the location and severity of pain is important, as it may be a sign that your underlying MF needs more aggressive treatment [16][17].

Planning for Surgeries and Procedures

If you need any type of surgery, your hematologist and surgeon must work together closely. Patients with MF face a dual risk: they are more likely to experience both blood clots (thrombosis) and excessive bleeding [18][19].

  • Individualized Planning: Perioperative planning depends heavily on your complete blood count, platelet function, and history. There is no one-size-fits-all target [18].
  • Medication Timing: Never start or stop a JAK inhibitor like ruxolitinib, or aspirin/anticoagulants, before surgery without a clear plan from your hematologist. Changing these medications without coordinated medical advice can cause severe inflammatory reactions or severe bleeding/clotting complications [20][21].
  • Bleeding Risks: Some patients with very high platelet counts can paradoxically develop a bleeding disorder called acquired von Willebrand syndrome. Your doctor may screen for this before you take aspirin or undergo surgery [21][22].

The Emotional Landscape

It is normal to feel “scan anxiety”—the stress that builds before a blood test or follow-up appointment. Acknowledging that your goals for treatment (such as reducing fatigue) may be different from your doctor’s goals (such as shrinking the spleen) is a key step in shared decision-making [2][23]. Engaging with patient support groups or a psycho-oncologist who understands chronic blood cancers can provide a safe space to manage the uncertainty of living with MF [24].

Common questions in this guide

How often will I need checkups for myelofibrosis?
The schedule depends on your risk level, treatment, and response. Monitoring may include weekly CBCs when starting a medicine such as ruxolitinib and every few months once treatment is stable, along with symptom and spleen checks. A repeat bone marrow biopsy or genetic test may be considered if blood counts change unexpectedly or progression is suspected.
What is the MPN-10, and why should I use it?
The MPN-10 is a symptom questionnaire that asks you to rate 10 common myelofibrosis-related symptoms from 0 to 10. Tracking scores over time can show whether symptoms such as fatigue, night sweats, or bone pain are changing and gives your doctor a consistent way to discuss them.
What can I do about fatigue or feeling full after a few bites?
For fatigue, pace yourself by breaking activities into smaller steps and planning rest periods instead of pushing through. If an enlarged spleen causes early fullness, try five or six small meals daily and choose nutrient-dense foods to help prevent unintended weight loss.
Why do I need a special plan before surgery or dental work?
Myelofibrosis can increase the risk of both blood clots and excessive bleeding during or around a procedure. Your hematologist and surgeon or dentist should review your blood counts, platelet function, medical history, and medicines to make an individualized plan.
Should I stop ruxolitinib, aspirin, or an anticoagulant before a procedure?
Do not start, stop, or change these medicines on your own. Your hematologist and procedural team need to coordinate the timing because abrupt or poorly planned changes can contribute to inflammatory reactions, bleeding, or clotting complications.
Can a very high platelet count cause bleeding in myelofibrosis?
Yes. Very high platelet counts can sometimes be linked with acquired von Willebrand syndrome, a bleeding disorder that may seem unexpected because the platelet count is high. Your doctor may test for it before recommending aspirin or performing surgery.
How can I cope with anxiety before myelofibrosis tests?
Stress before blood tests, scans, or follow-up visits is common and is sometimes called scan anxiety. Sharing your goals with your care team, using shared decision-making, and connecting with a patient support group or psycho-oncologist can help you manage uncertainty.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on myelofibrosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Do you have a preferred tool for me to use to track my symptoms, such as the MPN-10, and how often should I send you the results?
  2. 2.When is my next 'checkpoint' for a physical spleen exam or ultrasound, and what should I look for that might suggest it is growing?
  3. 3.If I need a routine procedure like a colonoscopy or dental surgery, how will you and the surgeon coordinate my aspirin and JAK inhibitor management?
  4. 4.Are there specific red flags in my CBC results, like a sudden drop in hemoglobin or a rise in blasts, that would trigger an unscheduled marrow biopsy?
  5. 5.Can you recommend a local or virtual support group for patients living with myeloproliferative neoplasms?

References

References (24)
  1. 1

    Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.

    Gerds AT, Gotlib J, Ali H, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2022; (20(9)):1033-1062.

    PMID: 36075392
  2. 2

    The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey.

    Harrison CN, Koschmieder S, Foltz L, et al.

    Annals of hematology 2017; (96(10)):1653-1665 doi:10.1007/s00277-017-3082-y.

    PMID: 28780729
  3. 3

    Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.

    Barbui T, Tefferi A, Vannucchi AM, et al.

    Leukemia 2018; (32(5)):1057-1069 doi:10.1038/s41375-018-0077-1.

    PMID: 29515238
  4. 4

    Management of classical Philadelphia chromosome-negative myeloproliferative neoplasms in Asia: consensus of the Asian Myeloid Working Group.

    Gill H, Leung GMK, Ooi MGM, et al.

    Clinical and experimental medicine 2023; (23(8)):4199-4217 doi:10.1007/s10238-023-01189-9.

    PMID: 37747591
  5. 5

    Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis.

    Devos T, Selleslag D, Granacher N, et al.

    Hematology (Amsterdam, Netherlands) 2022; (27(1)):23-31 doi:10.1080/16078454.2021.2009645.

    PMID: 34957926
  6. 6

    Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.

    Pardanani A, Harrison C, Cortes JE, et al.

    JAMA oncology 2015; (1(5)):643-51 doi:10.1001/jamaoncol.2015.1590.

    PMID: 26181658
  7. 7

    Development of a harmonized patient-reported outcome questionnaire to assess myelofibrosis symptoms in clinical trials.

    Gwaltney C, Paty J, Kwitkowski VE, et al.

    Leukemia research 2017; (59()):26-31 doi:10.1016/j.leukres.2017.05.012.

    PMID: 28544906
  8. 8

    Analysis of Predictive Factors for Early Response to Ruxolitinib in 320 Patients with Myelofibrosis From the Polish Adult Leukemia Group (PALG) Registry.

    Góra-Tybor J, Gołos A, Mikulski D, et al.

    Clinical lymphoma, myeloma & leukemia 2023; (23(1)):e19-e26 doi:10.1016/j.clml.2022.10.002.

    PMID: 36396583
  9. 9

    Spleen volume assessment in Ph-negative chronic myeloproliferative neoplasms: a real-life study comparing ultrasonography vs. magnetic resonance imaging scans.

    Pugliese N, Cavaliere C, Basso L, et al.

    Annals of hematology 2025; (104(1)):383-388 doi:10.1007/s00277-024-06177-x.

    PMID: 39836191
  10. 10

    Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.

    Tefferi A

    American journal of hematology 2023; (98(5)):801-821 doi:10.1002/ajh.26857.

    PMID: 36680511
  11. 11

    Progression in Ph-Chromosome-Negative Myeloproliferative Neoplasms: An Overview on Pathologic Issues and Molecular Determinants.

    Sabattini E, Pizzi M, Agostinelli C, et al.

    Cancers 2021; (13(21)) doi:10.3390/cancers13215531.

    PMID: 34771693
  12. 12

    Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib.

    Davis KL, Côté I, Kaye JA, et al.

    Advances in hematology 2015; (2015()):848473 doi:10.1155/2015/848473.

    PMID: 26635878
  13. 13

    Modern management of splenomegaly in patients with myelofibrosis.

    Tremblay D, Schwartz M, Bakst R, et al.

    Annals of hematology 2020; (99(7)):1441-1451 doi:10.1007/s00277-020-04069-4.

    PMID: 32417942
  14. 14

    Next Generation Therapeutics for the Treatment of Myelofibrosis.

    Tremblay D, Mascarenhas J

    Cells 2021; (10(5)) doi:10.3390/cells10051034.

    PMID: 33925695
  15. 15

    Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.

    Harrison CN, Schaap N, Vannucchi AM, et al.

    The Lancet. Haematology 2017; (4(7)):e317-e324 doi:10.1016/S2352-3026(17)30088-1.

    PMID: 28602585
  16. 16

    Osteolytic bone lesions in patients with primary myelofibrosis: A systematic review.

    Battukh N, Ali E, Yassin M

    Acta bio-medica : Atenei Parmensis 2022; (92(6)):e2021478 doi:10.23750/abm.v92i6.12350.

    PMID: 35075062
  17. 17

    Diffuse FAPI-46 Uptake in Bone Marrow: A Case of Primary Myelofibrosis With Superscan Pattern on Bone Scintigraphy.

    Elahifard H, Raeisi N, Saber Tanha A, et al.

    Clinical nuclear medicine 2025; (50(12)):e686-e688 doi:10.1097/RLU.0000000000005862.

    PMID: 40611460
  18. 18

    A Review About the Assessment of the Bleeding and Thrombosis Risk for Patients With Myeloproliferative Neoplasms Scheduled for Surgery.

    Andreescu M, Andreescu B

    Cureus 2024; (16(3)):e56008 doi:10.7759/cureus.56008.

    PMID: 38606222
  19. 19

    Thrombotic and Hemorrhagic Issues Associated with Myeloproliferative Neoplasms.

    Papageorgiou L, Elalamy I, Vandreden P, Gerotziafas GT

    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2022; (28()):10760296221097969 doi:10.1177/10760296221097969.

    PMID: 35733370
  20. 20

    Philadelphia-Negative Myeloproliferative Neoplasms Around the COVID-19 Pandemic.

    Barbui T, De Stefano V

    Current hematologic malignancy reports 2021; (16(5)):455-463 doi:10.1007/s11899-021-00647-z.

    PMID: 34586561
  21. 21

    Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.

    Tefferi A, Barbui T

    American journal of hematology 2015; (90(2)):162-73 doi:10.1002/ajh.23895.

    PMID: 25611051
  22. 22

    Practical management of the haemorrhagic complications of myeloproliferative neoplasms.

    Jones E, Dillon B, Swan D, Thachil J

    British journal of haematology 2022; (199(3)):313-321 doi:10.1111/bjh.18322.

    PMID: 35724983
  23. 23

    From symptom scales to regulatory endpoints: the evolution and clinical impact of patient-reported outcome measures in myeloproliferative neoplasms.

    Chen M, Zheng C, Xie J, et al.

    Clinical and experimental medicine 2025; (25(1)):330 doi:10.1007/s10238-025-01830-9.

    PMID: 41138008
  24. 24

    Approach to MPN Symptom Assessment.

    Geyer H, Mesa RA

    Current hematologic malignancy reports 2017; (12(5)):381-388 doi:10.1007/s11899-017-0399-5.

    PMID: 28942516

This page is for informational purposes only and does not constitute medical advice about your myelofibrosis. Do not change ruxolitinib, aspirin, or anticoagulants or plan a procedure without guidance from your hematologist and surgical team.